Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

- PMLiVE

Pfizer to acquire Seagen for $43bn in biggest pharma transaction since 2019

The deal includes four approved medicines and Seagen’s antibody-drug conjugate technology

- PMLiVE

Janssen’s single tablet combination shows promise in phase 3 PAH study

Around 500 to 1,000 cases of pulmonary arterial hypertension are diagnosed each year in the US

- PMLiVE

Novo Nordisk’s weight-loss drug recommended by NICE

The drug, semaglutide, will be offered to eligible adults for a maximum of two years

Medscape Oncology: Delivering Impact at ASH

You can read more information on Medscape Oncology at ASH here, or please reach out to Chris Carey or Steve Dunn who can tell you more about how Medscape can help to...

Medscape Education Global

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

Janssen reports updated phase 3 results for niraparib combination in prostate cancer

Prostate cancer is the most common cancer affecting men in Europe

- PMLiVE

Ipsen to acquire worldwide rights to pre-clinical stage oncology programme

The company has an existing partnership with the Université de Montréal and IRICoR

- PMLiVE

ICR discovery could lead to new series of cancer drugs

The team found new inhibitors that block the action of a cancer-driving protein

- PMLiVE

Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients

Kate Shaw, Innovative Trials' Founder & CEM, reflects on the exciting news for patients affected by cancer in the UK.

Innovative Trials

- PMLiVE

Novo Nordisk’s type 2 diabetes drug approved by FDA as first-line option

Rybelsus was initially approved in 2019 as a second-line treatment

- PMLiVE

California sues largest US insulin manufacturers and PBMs for overpricing

Eli Lilly, Novo Nordisk and Sanofi produce over 90% of the global insulin supply

- PMLiVE

Genentech and Kronos Bio announce oncology partnership worth over $570m

The companies aim to advance novel therapies for transcriptional targets in oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links